Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors
Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors
Status: Enrolling
Updated:  4/27/2017
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors
Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors
Status: Enrolling
Updated: 4/27/2017
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Click here to add this to my saved trials
Safety Study of Radio-labeled huA33 Antibody in Colorectal Cancer
A Pilot Study of Radioimmunodetection of 124-Iodine-labeled Humanized A33 Antibody (124I-huA33) in Patients With Colorectal Cancer
Status: Enrolling
Updated:  5/1/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Safety Study of Radio-labeled huA33 Antibody in Colorectal Cancer
A Pilot Study of Radioimmunodetection of 124-Iodine-labeled Humanized A33 Antibody (124I-huA33) in Patients With Colorectal Cancer
Status: Enrolling
Updated: 5/1/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Defining an Exposure Target for Weekly Paclitaxel Infusion in Breast Cancer Patients
Defining an Exposure Target for Weekly Paclitaxel Infusion in Breast Cancer Patients
Status: Enrolling
Updated:  5/1/2017
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Defining an Exposure Target for Weekly Paclitaxel Infusion in Breast Cancer Patients
Defining an Exposure Target for Weekly Paclitaxel Infusion in Breast Cancer Patients
Status: Enrolling
Updated: 5/1/2017
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
DNA in Predicting Response After Systemic Therapy in Women With Metastatic Breast Cancer
DNA Methylation in Serum as a Predictive Marker of Progression and Survival Following Systemic Therapy in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  5/1/2017
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
DNA in Predicting Response After Systemic Therapy in Women With Metastatic Breast Cancer
DNA Methylation in Serum as a Predictive Marker of Progression and Survival Following Systemic Therapy in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 5/1/2017
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
DNA in Predicting Response After Systemic Therapy in Women With Metastatic Breast Cancer
DNA Methylation in Serum as a Predictive Marker of Progression and Survival Following Systemic Therapy in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  5/1/2017
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
DNA in Predicting Response After Systemic Therapy in Women With Metastatic Breast Cancer
DNA Methylation in Serum as a Predictive Marker of Progression and Survival Following Systemic Therapy in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 5/1/2017
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Click here to add this to my saved trials
DNA in Predicting Response After Systemic Therapy in Women With Metastatic Breast Cancer
DNA Methylation in Serum as a Predictive Marker of Progression and Survival Following Systemic Therapy in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  5/1/2017
Mayo Clinic Cancer Center
mi
from
Rochester, MN
DNA in Predicting Response After Systemic Therapy in Women With Metastatic Breast Cancer
DNA Methylation in Serum as a Predictive Marker of Progression and Survival Following Systemic Therapy in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 5/1/2017
Mayo Clinic Cancer Center
mi
from
Rochester, MN
Click here to add this to my saved trials
DNA in Predicting Response After Systemic Therapy in Women With Metastatic Breast Cancer
DNA Methylation in Serum as a Predictive Marker of Progression and Survival Following Systemic Therapy in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  5/1/2017
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
mi
from
Chapel Hill, NC
DNA in Predicting Response After Systemic Therapy in Women With Metastatic Breast Cancer
DNA Methylation in Serum as a Predictive Marker of Progression and Survival Following Systemic Therapy in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 5/1/2017
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
The Biorepository for Scripps Health
The Biorepository for Scripps Health
Status: Enrolling
Updated:  5/2/2017
Scripps Mercy Hospital
mi
from
San Diego, CA
The Biorepository for Scripps Health
The Biorepository for Scripps Health
Status: Enrolling
Updated: 5/2/2017
Scripps Mercy Hospital
mi
from
San Diego, CA
Click here to add this to my saved trials
NCGENES: North Carolina Clinical Genomic Evaluation by NextGen Exome Sequencing
NCGENES: North Carolina Clinical Genomic Evaluation by NextGen Exome Sequencing
Status: Enrolling
Updated:  5/2/2017
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
NCGENES: North Carolina Clinical Genomic Evaluation by NextGen Exome Sequencing
NCGENES: North Carolina Clinical Genomic Evaluation by NextGen Exome Sequencing
Status: Enrolling
Updated: 5/2/2017
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Evaluation Of Transperineal Ultrasound For Image Guidance In The Treatment Of Prostate Cancer in Men Following Prostatectomy
Status: Enrolling
Updated:  5/2/2017
Radiation Oncology, Fletcher Allen Healthcare
mi
from
Burlington, VT
Evaluation Of Transperineal Ultrasound For Image Guidance In The Treatment Of Prostate Cancer in Men Following Prostatectomy
Status: Enrolling
Updated: 5/2/2017
Radiation Oncology, Fletcher Allen Healthcare
mi
from
Burlington, VT
Click here to add this to my saved trials
A Safety Study of 18F-DCFPyL, a PSMA-based PET Radiotracer, in Patients With Advanced Prostate Cancer
Phase 1 Biodistribution and Pharmacokinetic Study of 18F-DCFPyL, a Second Generation Low-molecular Weight PSMA-based PET Radiotracer, in Patients With Advanced Prostate Cancer
Status: Enrolling
Updated:  5/2/2017
Johns Hopkins University
mi
from
Baltimore, MD
A Safety Study of 18F-DCFPyL, a PSMA-based PET Radiotracer, in Patients With Advanced Prostate Cancer
Phase 1 Biodistribution and Pharmacokinetic Study of 18F-DCFPyL, a Second Generation Low-molecular Weight PSMA-based PET Radiotracer, in Patients With Advanced Prostate Cancer
Status: Enrolling
Updated: 5/2/2017
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Women's Healthy Eating and Living Study
Dietary Intervention in Women Who Have Been Treated For Stage I, Stage II, or Stage III Breast Cancer: Women's Healthy Eating and Living (WHEL) Study
Status: Enrolling
Updated:  5/2/2017
Arizona Cancer Center
mi
from
Tucson, AZ
Women's Healthy Eating and Living Study
Dietary Intervention in Women Who Have Been Treated For Stage I, Stage II, or Stage III Breast Cancer: Women's Healthy Eating and Living (WHEL) Study
Status: Enrolling
Updated: 5/2/2017
Arizona Cancer Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
Women's Healthy Eating and Living Study
Dietary Intervention in Women Who Have Been Treated For Stage I, Stage II, or Stage III Breast Cancer: Women's Healthy Eating and Living (WHEL) Study
Status: Enrolling
Updated:  5/2/2017
University of California San Diego Cancer Center
mi
from
La Jolla, CA
Women's Healthy Eating and Living Study
Dietary Intervention in Women Who Have Been Treated For Stage I, Stage II, or Stage III Breast Cancer: Women's Healthy Eating and Living (WHEL) Study
Status: Enrolling
Updated: 5/2/2017
University of California San Diego Cancer Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
Women's Healthy Eating and Living Study
Dietary Intervention in Women Who Have Been Treated For Stage I, Stage II, or Stage III Breast Cancer: Women's Healthy Eating and Living (WHEL) Study
Status: Enrolling
Updated:  5/2/2017
Permanente Medical Group (060)
mi
from
Oakland, CA
Women's Healthy Eating and Living Study
Dietary Intervention in Women Who Have Been Treated For Stage I, Stage II, or Stage III Breast Cancer: Women's Healthy Eating and Living (WHEL) Study
Status: Enrolling
Updated: 5/2/2017
Permanente Medical Group (060)
mi
from
Oakland, CA
Click here to add this to my saved trials
Women's Healthy Eating and Living Study
Dietary Intervention in Women Who Have Been Treated For Stage I, Stage II, or Stage III Breast Cancer: Women's Healthy Eating and Living (WHEL) Study
Status: Enrolling
Updated:  5/2/2017
University of California Davis School of Medicine
mi
from
Sacramento, CA
Women's Healthy Eating and Living Study
Dietary Intervention in Women Who Have Been Treated For Stage I, Stage II, or Stage III Breast Cancer: Women's Healthy Eating and Living (WHEL) Study
Status: Enrolling
Updated: 5/2/2017
University of California Davis School of Medicine
mi
from
Sacramento, CA
Click here to add this to my saved trials
Women's Healthy Eating and Living Study
Dietary Intervention in Women Who Have Been Treated For Stage I, Stage II, or Stage III Breast Cancer: Women's Healthy Eating and Living (WHEL) Study
Status: Enrolling
Updated:  5/2/2017
Northern California Cancer Center
mi
from
Union City, CA
Women's Healthy Eating and Living Study
Dietary Intervention in Women Who Have Been Treated For Stage I, Stage II, or Stage III Breast Cancer: Women's Healthy Eating and Living (WHEL) Study
Status: Enrolling
Updated: 5/2/2017
Northern California Cancer Center
mi
from
Union City, CA
Click here to add this to my saved trials
Women's Healthy Eating and Living Study
Dietary Intervention in Women Who Have Been Treated For Stage I, Stage II, or Stage III Breast Cancer: Women's Healthy Eating and Living (WHEL) Study
Status: Enrolling
Updated:  5/2/2017
Center for Health Research - Portland
mi
from
Portland, OR
Women's Healthy Eating and Living Study
Dietary Intervention in Women Who Have Been Treated For Stage I, Stage II, or Stage III Breast Cancer: Women's Healthy Eating and Living (WHEL) Study
Status: Enrolling
Updated: 5/2/2017
Center for Health Research - Portland
mi
from
Portland, OR
Click here to add this to my saved trials
Women's Healthy Eating and Living Study
Dietary Intervention in Women Who Have Been Treated For Stage I, Stage II, or Stage III Breast Cancer: Women's Healthy Eating and Living (WHEL) Study
Status: Enrolling
Updated:  5/2/2017
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Women's Healthy Eating and Living Study
Dietary Intervention in Women Who Have Been Treated For Stage I, Stage II, or Stage III Breast Cancer: Women's Healthy Eating and Living (WHEL) Study
Status: Enrolling
Updated: 5/2/2017
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Bioimpedance Spectroscopy in Detecting Lower-Extremity Lymphedema in Patients With Stage I, Stage II, Stage III, or Stage IV Vulvar Cancer Undergoing Surgery and Lymphadenectomy
A Limited Access Phase II Trial Utilizing Bioimpedance to Measure Lower Extremity Lymphedema Associated With the Surgical Management of a Vulvar Cancer
Status: Enrolling
Updated:  5/3/2017
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Bioimpedance Spectroscopy in Detecting Lower-Extremity Lymphedema in Patients With Stage I, Stage II, Stage III, or Stage IV Vulvar Cancer Undergoing Surgery and Lymphadenectomy
A Limited Access Phase II Trial Utilizing Bioimpedance to Measure Lower Extremity Lymphedema Associated With the Surgical Management of a Vulvar Cancer
Status: Enrolling
Updated: 5/3/2017
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Click here to add this to my saved trials
Bioimpedance Spectroscopy in Detecting Lower-Extremity Lymphedema in Patients With Stage I, Stage II, Stage III, or Stage IV Vulvar Cancer Undergoing Surgery and Lymphadenectomy
A Limited Access Phase II Trial Utilizing Bioimpedance to Measure Lower Extremity Lymphedema Associated With the Surgical Management of a Vulvar Cancer
Status: Enrolling
Updated:  5/3/2017
Mercy Hospital Springfield
mi
from
Springfield, MO
Bioimpedance Spectroscopy in Detecting Lower-Extremity Lymphedema in Patients With Stage I, Stage II, Stage III, or Stage IV Vulvar Cancer Undergoing Surgery and Lymphadenectomy
A Limited Access Phase II Trial Utilizing Bioimpedance to Measure Lower Extremity Lymphedema Associated With the Surgical Management of a Vulvar Cancer
Status: Enrolling
Updated: 5/3/2017
Mercy Hospital Springfield
mi
from
Springfield, MO
Click here to add this to my saved trials
Bioimpedance Spectroscopy in Detecting Lower-Extremity Lymphedema in Patients With Stage I, Stage II, Stage III, or Stage IV Vulvar Cancer Undergoing Surgery and Lymphadenectomy
A Limited Access Phase II Trial Utilizing Bioimpedance to Measure Lower Extremity Lymphedema Associated With the Surgical Management of a Vulvar Cancer
Status: Enrolling
Updated:  5/3/2017
Women's Cancer Center of Nevada
mi
from
Las Vegas, NV
Bioimpedance Spectroscopy in Detecting Lower-Extremity Lymphedema in Patients With Stage I, Stage II, Stage III, or Stage IV Vulvar Cancer Undergoing Surgery and Lymphadenectomy
A Limited Access Phase II Trial Utilizing Bioimpedance to Measure Lower Extremity Lymphedema Associated With the Surgical Management of a Vulvar Cancer
Status: Enrolling
Updated: 5/3/2017
Women's Cancer Center of Nevada
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Bioimpedance Spectroscopy in Detecting Lower-Extremity Lymphedema in Patients With Stage I, Stage II, Stage III, or Stage IV Vulvar Cancer Undergoing Surgery and Lymphadenectomy
A Limited Access Phase II Trial Utilizing Bioimpedance to Measure Lower Extremity Lymphedema Associated With the Surgical Management of a Vulvar Cancer
Status: Enrolling
Updated:  5/3/2017
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Bioimpedance Spectroscopy in Detecting Lower-Extremity Lymphedema in Patients With Stage I, Stage II, Stage III, or Stage IV Vulvar Cancer Undergoing Surgery and Lymphadenectomy
A Limited Access Phase II Trial Utilizing Bioimpedance to Measure Lower Extremity Lymphedema Associated With the Surgical Management of a Vulvar Cancer
Status: Enrolling
Updated: 5/3/2017
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Bioimpedance Spectroscopy in Detecting Lower-Extremity Lymphedema in Patients With Stage I, Stage II, Stage III, or Stage IV Vulvar Cancer Undergoing Surgery and Lymphadenectomy
A Limited Access Phase II Trial Utilizing Bioimpedance to Measure Lower Extremity Lymphedema Associated With the Surgical Management of a Vulvar Cancer
Status: Enrolling
Updated:  5/3/2017
University of Wisconsin Hospital and Clinics
mi
from
Madison, WI
Bioimpedance Spectroscopy in Detecting Lower-Extremity Lymphedema in Patients With Stage I, Stage II, Stage III, or Stage IV Vulvar Cancer Undergoing Surgery and Lymphadenectomy
A Limited Access Phase II Trial Utilizing Bioimpedance to Measure Lower Extremity Lymphedema Associated With the Surgical Management of a Vulvar Cancer
Status: Enrolling
Updated: 5/3/2017
University of Wisconsin Hospital and Clinics
mi
from
Madison, WI
Click here to add this to my saved trials
Bioimpedance Spectroscopy in Detecting Lower-Extremity Lymphedema in Patients With Stage I, Stage II, Stage III, or Stage IV Vulvar Cancer Undergoing Surgery and Lymphadenectomy
A Limited Access Phase II Trial Utilizing Bioimpedance to Measure Lower Extremity Lymphedema Associated With the Surgical Management of a Vulvar Cancer
Status: Enrolling
Updated:  5/3/2017
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Bioimpedance Spectroscopy in Detecting Lower-Extremity Lymphedema in Patients With Stage I, Stage II, Stage III, or Stage IV Vulvar Cancer Undergoing Surgery and Lymphadenectomy
A Limited Access Phase II Trial Utilizing Bioimpedance to Measure Lower Extremity Lymphedema Associated With the Surgical Management of a Vulvar Cancer
Status: Enrolling
Updated: 5/3/2017
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Bioimpedance Spectroscopy in Detecting Lower-Extremity Lymphedema in Patients With Stage I, Stage II, Stage III, or Stage IV Vulvar Cancer Undergoing Surgery and Lymphadenectomy
A Limited Access Phase II Trial Utilizing Bioimpedance to Measure Lower Extremity Lymphedema Associated With the Surgical Management of a Vulvar Cancer
Status: Enrolling
Updated:  5/3/2017
University of Minnesota, Masonic Cancer Center
mi
from
Minneapolis, MN
Bioimpedance Spectroscopy in Detecting Lower-Extremity Lymphedema in Patients With Stage I, Stage II, Stage III, or Stage IV Vulvar Cancer Undergoing Surgery and Lymphadenectomy
A Limited Access Phase II Trial Utilizing Bioimpedance to Measure Lower Extremity Lymphedema Associated With the Surgical Management of a Vulvar Cancer
Status: Enrolling
Updated: 5/3/2017
University of Minnesota, Masonic Cancer Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Bioimpedance Spectroscopy in Detecting Lower-Extremity Lymphedema in Patients With Stage I, Stage II, Stage III, or Stage IV Vulvar Cancer Undergoing Surgery and Lymphadenectomy
A Limited Access Phase II Trial Utilizing Bioimpedance to Measure Lower Extremity Lymphedema Associated With the Surgical Management of a Vulvar Cancer
Status: Enrolling
Updated:  5/3/2017
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Bioimpedance Spectroscopy in Detecting Lower-Extremity Lymphedema in Patients With Stage I, Stage II, Stage III, or Stage IV Vulvar Cancer Undergoing Surgery and Lymphadenectomy
A Limited Access Phase II Trial Utilizing Bioimpedance to Measure Lower Extremity Lymphedema Associated With the Surgical Management of a Vulvar Cancer
Status: Enrolling
Updated: 5/3/2017
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Bioimpedance Spectroscopy in Detecting Lower-Extremity Lymphedema in Patients With Stage I, Stage II, Stage III, or Stage IV Vulvar Cancer Undergoing Surgery and Lymphadenectomy
A Limited Access Phase II Trial Utilizing Bioimpedance to Measure Lower Extremity Lymphedema Associated With the Surgical Management of a Vulvar Cancer
Status: Enrolling
Updated:  5/3/2017
M D Anderson Cancer Center
mi
from
Houston, TX
Bioimpedance Spectroscopy in Detecting Lower-Extremity Lymphedema in Patients With Stage I, Stage II, Stage III, or Stage IV Vulvar Cancer Undergoing Surgery and Lymphadenectomy
A Limited Access Phase II Trial Utilizing Bioimpedance to Measure Lower Extremity Lymphedema Associated With the Surgical Management of a Vulvar Cancer
Status: Enrolling
Updated: 5/3/2017
M D Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Bioimpedance Spectroscopy in Detecting Lower-Extremity Lymphedema in Patients With Stage I, Stage II, Stage III, or Stage IV Vulvar Cancer Undergoing Surgery and Lymphadenectomy
A Limited Access Phase II Trial Utilizing Bioimpedance to Measure Lower Extremity Lymphedema Associated With the Surgical Management of a Vulvar Cancer
Status: Enrolling
Updated:  5/3/2017
Saint Vincent Hospital and Health Care Center
mi
from
Indianapolis, IN
Bioimpedance Spectroscopy in Detecting Lower-Extremity Lymphedema in Patients With Stage I, Stage II, Stage III, or Stage IV Vulvar Cancer Undergoing Surgery and Lymphadenectomy
A Limited Access Phase II Trial Utilizing Bioimpedance to Measure Lower Extremity Lymphedema Associated With the Surgical Management of a Vulvar Cancer
Status: Enrolling
Updated: 5/3/2017
Saint Vincent Hospital and Health Care Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Bioimpedance Spectroscopy in Detecting Lower-Extremity Lymphedema in Patients With Stage I, Stage II, Stage III, or Stage IV Vulvar Cancer Undergoing Surgery and Lymphadenectomy
A Limited Access Phase II Trial Utilizing Bioimpedance to Measure Lower Extremity Lymphedema Associated With the Surgical Management of a Vulvar Cancer
Status: Enrolling
Updated:  5/3/2017
Oklahoma Cancer Specialists and Research Institute-Tulsa
mi
from
Tulsa, OK
Bioimpedance Spectroscopy in Detecting Lower-Extremity Lymphedema in Patients With Stage I, Stage II, Stage III, or Stage IV Vulvar Cancer Undergoing Surgery and Lymphadenectomy
A Limited Access Phase II Trial Utilizing Bioimpedance to Measure Lower Extremity Lymphedema Associated With the Surgical Management of a Vulvar Cancer
Status: Enrolling
Updated: 5/3/2017
Oklahoma Cancer Specialists and Research Institute-Tulsa
mi
from
Tulsa, OK
Click here to add this to my saved trials
LifeCourse: A Supportive Care Approach for Patients Late in Life
LifeCourse: A Supportive Care Approach for Patients Late in Life
Status: Enrolling
Updated:  5/3/2017
Abbott Northwestern Hospital
mi
from
Minneapolis, MN
LifeCourse: A Supportive Care Approach for Patients Late in Life
LifeCourse: A Supportive Care Approach for Patients Late in Life
Status: Enrolling
Updated: 5/3/2017
Abbott Northwestern Hospital
mi
from
Minneapolis, MN
Click here to add this to my saved trials
LifeCourse: A Supportive Care Approach for Patients Late in Life
LifeCourse: A Supportive Care Approach for Patients Late in Life
Status: Enrolling
Updated:  5/3/2017
Augustana Health Care Center
mi
from
Minneapolis, MN
LifeCourse: A Supportive Care Approach for Patients Late in Life
LifeCourse: A Supportive Care Approach for Patients Late in Life
Status: Enrolling
Updated: 5/3/2017
Augustana Health Care Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
LifeCourse: A Supportive Care Approach for Patients Late in Life
LifeCourse: A Supportive Care Approach for Patients Late in Life
Status: Enrolling
Updated:  5/3/2017
Walker Methodist Health Center
mi
from
Minneapolis, MN
LifeCourse: A Supportive Care Approach for Patients Late in Life
LifeCourse: A Supportive Care Approach for Patients Late in Life
Status: Enrolling
Updated: 5/3/2017
Walker Methodist Health Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Clinical Validation of a Predictive Model for the Presence of Cervical Lymph Node Metastasis in Papillary Thyroid Cancer
Clinical Validation of a Predictive Model for the Presence of Cervical Lymph Node Metastasis in Papillary Thyroid Cancer
Status: Enrolling
Updated:  5/3/2017
Rebecca J Guigli
mi
from
Aurora, CO
Clinical Validation of a Predictive Model for the Presence of Cervical Lymph Node Metastasis in Papillary Thyroid Cancer
Clinical Validation of a Predictive Model for the Presence of Cervical Lymph Node Metastasis in Papillary Thyroid Cancer
Status: Enrolling
Updated: 5/3/2017
Rebecca J Guigli
mi
from
Aurora, CO
Click here to add this to my saved trials
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated:  5/4/2017
Birmingham Hematology and Oncology
mi
from
Bessemer, AL
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated: 5/4/2017
Birmingham Hematology and Oncology
mi
from
Bessemer, AL
Click here to add this to my saved trials
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated:  5/4/2017
Birmingham Hematology and Oncology - Pilot
mi
from
Birmingham, AL
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated: 5/4/2017
Birmingham Hematology and Oncology - Pilot
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated:  5/4/2017
Birmingham Hematology and Oncology - Brookwood
mi
from
Birmingham, AL
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated: 5/4/2017
Birmingham Hematology and Oncology - Brookwood
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated:  5/4/2017
Birmingham Hematology and Oncology - Montclair
mi
from
Birmingham, AL
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated: 5/4/2017
Birmingham Hematology and Oncology - Montclair
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated:  5/4/2017
Birmingham Hematology and Oncology - Princeton
mi
from
Birmingham, AL
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated: 5/4/2017
Birmingham Hematology and Oncology - Princeton
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated:  5/4/2017
Northern Arizona Hematology & Onclogy Associates
mi
from
Flagstaff, AZ
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated: 5/4/2017
Northern Arizona Hematology & Onclogy Associates
mi
from
Flagstaff, AZ
Click here to add this to my saved trials
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated:  5/4/2017
Arizona Oncolocy (CASA-Green Valley)
mi
from
Green Valley, AZ
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated: 5/4/2017
Arizona Oncolocy (CASA-Green Valley)
mi
from
Green Valley, AZ
Click here to add this to my saved trials
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated:  5/4/2017
Arizona Oncology (CASA- Oro Valley)
mi
from
Oro Valley, AZ
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated: 5/4/2017
Arizona Oncology (CASA- Oro Valley)
mi
from
Oro Valley, AZ
Click here to add this to my saved trials
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated:  5/4/2017
Hematology Oncology Associates
mi
from
Phoenix, AZ
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated: 5/4/2017
Hematology Oncology Associates
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated:  5/4/2017
Northern Arizona Hematology & Oncology Associates
mi
from
Sedona, AZ
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated: 5/4/2017
Northern Arizona Hematology & Oncology Associates
mi
from
Sedona, AZ
Click here to add this to my saved trials
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated:  5/4/2017
Arizona Oncology (CASA-Safford)
mi
from
Safford, AZ
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated: 5/4/2017
Arizona Oncology (CASA-Safford)
mi
from
Safford, AZ
Click here to add this to my saved trials
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated:  5/4/2017
Arizona Oncology Associates - Rudasill
mi
from
Tucson, AZ
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated: 5/4/2017
Arizona Oncology Associates - Rudasill
mi
from
Tucson, AZ
Click here to add this to my saved trials
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated:  5/4/2017
Arizona Oncology (CASA-Craycroft)
mi
from
Tucson, AZ
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated: 5/4/2017
Arizona Oncology (CASA-Craycroft)
mi
from
Tucson, AZ
Click here to add this to my saved trials
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated:  5/4/2017
Central Hematology/Oncology Medical Group, Inc.
mi
from
Alhambra, CA
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated: 5/4/2017
Central Hematology/Oncology Medical Group, Inc.
mi
from
Alhambra, CA
Click here to add this to my saved trials
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated:  5/4/2017
Kaiser Permanente - Fremont
mi
from
Fremont, CA
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated: 5/4/2017
Kaiser Permanente - Fremont
mi
from
Fremont, CA
Click here to add this to my saved trials
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated:  5/4/2017
St. Jude Heritage Healthcare
mi
from
Fullerton, CA
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated: 5/4/2017
St. Jude Heritage Healthcare
mi
from
Fullerton, CA
Click here to add this to my saved trials
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated:  5/4/2017
Kaiser Permanente Medical Center - Hayward
mi
from
Hayward, CA
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
A Phase III Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status: Enrolling
Updated: 5/4/2017
Kaiser Permanente Medical Center - Hayward
mi
from
Hayward, CA
Click here to add this to my saved trials